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Abstract
Background: Pandemics of new and emerging infectious diseases are unpredictable, 
recurrent events that rapidly threaten global health and security. We aimed to identify 
public views regarding provision of information and consent to participate in primary 
and critical care clinical research during a future influenza- like illness pandemic.
Methods: Descriptive- interpretive qualitative study, using focus groups (n = 10) and 
semi- structured interviews (n = 16), with 80 members of the public (>18 years) in 
Belgium, Spain, Poland and the UK. Local qualitative researchers followed a scenario- 
based topic guide to collect data. Data were transcribed verbatim, translated into 
English and subject to framework analysis.
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1  | INTRODUCTION
Pandemics and epidemics of new and re- emerging infectious disease 
are unpredictable but recurrent events that threaten global health 
and socio- economic security. It is of utmost importance to human 
health that there is capacity to conduct time- critical, patient- centred 
research during a pandemic because such research offers the best 
strategy for mitigating impact on health and society.1–3 Such research 
is necessary to help clinicians accurately diagnose and provide opti-
mal treatment, to develop preventive interventions such as vaccines, 
and for policymakers to make decisions about strategies to prevent 
spread and mobilize health- care services. One of the major conclu-
sions from the, fortuitously mild, 2009 H1N1 pandemic is that glob-
ally co- ordinated research capacity that can be rapidly mobilized is 
lacking.
Globally, the call has been made for pandemic planning to in-
corporate preparedness and capacity for conducting prospective 
patient- focused clinical research.2,4 Such research should be relevant, 
methodologically rigorous and be held to the same standards of ethi-
cal conduct as research conducted in non- emergent times.5 However, 
there are numerous barriers to conducting clinical studies during a 
public health emergency, not least of which is ensuring that partici-
pants have sufficient information and opportunity in which to make 
valid, informed decision about research participation. Routine research 
enrolment processes, which are both appropriate and important under 
usual circumstances, might be both disproportionate and counter-
productive during a serious pandemic. The potential threat to human 
health that would occur with a serious pandemic is of such a mag-
nitude that we must examine all barriers that prevent us conducting 
effective clinical research. An important but seldom examined consid-
eration, when balancing the rights and protection of research partic-
ipants against the public health impact of research, is the views and 
opinions of prospective research participants themselves.
The objective of this study was to ascertain the opinions of mem-
bers of the public in four European countries regarding provision of 
information and consent to participate in research that should apply 
during a pandemic. Specifically, we sought to describe public under-
standings of pandemics and related research, to identify factors that 
influence people’s decisions regarding research participation and to 
consider acceptability of alternate methods of enrolment to clinical 
research during a pandemic.
2  | METHODS
2.1 | Design and setting
This study was conducted as part of the European Commission 
funded Platform foR European Preparedness Against (Re- )emerging 
Epidemics consortium (PREPARE; www.prepare.eu). It aims to inform 
study optimization of multisite, pan European clinical studies in pri-
mary and critical care for over 5000 patients during interpandemic 
periods and in preparedness for a research response during a future 
pandemic. We used qualitative research methodology because we 
aimed to identify important issues from the perspectives of the public 
before attempting to quantify them. We therefore prioritized quality 
and richness of information gathering over quantity or prevalence of 
views. This work has informed construction of a survey instrument 
that is being applied to a large, representative sample.
Results: Public understandings of pandemics were shaped by personal factors (illness 
during the previous H1N1 pandemic, experience of life- threatening illness) and social 
factors (historical references, media, public health information). Informants appreci-
ated safeguards provided by ethically robust research procedures, but current enrol-
ment procedures were seen as a barrier. They proposed simplified enrolment processes 
for higher risk research and consent waiver for certain types of low- risk research. 
Decision making about research participation was influenced by contextual, research 
and personal factors. Informants generally either carefully weighed up various ap-
proaches to research participation or responded instinctively. They supported the prin-
ciple of using routinely collected, anonymized clinical biological samples for research 
without explicit consent, but regarded this as less acceptable if researchers were moti-
vated primarily by commercial gain.
Conclusions: This bottom- up approach to ascertaining public views on pandemic clini-
cal research has identified support for more proportionate research protection proce-
dures for publically funded, low- risk studies.
K E Y W O R D S
epidemic, infectious disease outbreak, influenza, informed consent, pandemic, patient and public 
involvement
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2.2 | Recruitment and sampling
We selected one country each from northern, southern, eastern 
and western Europe, as defined by the United Nations macro- 
geographical regions.6 Focus groups and interviews took place be-
tween July and November 2015 in Cardiff, UK; Barcelona, Spain; 
Lodz, Poland; Antwerp and Bruges, Belgium. These locations also had 
teams that were members of the PREPARE consortium recruiting 
patients into pandemic research. Additionally, their health services 
differ in important, contrasting ways (eg fee for service and free at 
the point of delivery). Local, experienced qualitative researchers with 
good command of the English language were recruited through pre- 
existing research networks. Informants (>18 years) within the four 
countries were purposively sampled to include parents, carers and 
informants with experience of hospital admission. Participant recruit-
ment was by local advertisement. Interested respondents completed 
a short demographic questionnaire before being invited to attend the 
group.
2.3 | Data collection
Focus groups and semi- structured individual interviews were used. 
Our rationale for using focus groups was to stimulate discussion be-
tween those involved, anticipating that this would give rise to varied 
ideas and perspectives beyond those of the research team.7,8 We held 
10 two- hour focus groups. Topic guides were developed iteratively 
in two pilot focus groups (UK). Two focus groups were subsequently 
held in each of the four countries in accessible community venues. 
Pilot data were included in the data corpus as there were no substan-
tive changes to data collection procedures that invalidated their use. 
We conducted 16 follow- up telephone interviews (15- 30 minutes in 
length) within 2- 7 days of focus groups with two informants from 
each group. We selected interviewees for these individual interviews 
who were less vocal in the group or those who had held discrep-
ant or contrasting views.7 Focus groups and interviews were con-
ducted in the local language. A face- to- face training meeting of all 
focus group moderators was held prior to data collection to ensure 
consistency, cultural sensitivity and to inform reflexivity. All study 
materials were translated into local languages. Focus groups were 
conducted in the local language by two local researchers (one mod-
erator and one observer). Local researchers came from a range of 
different backgrounds (sociology, primary care, public health, culture 
science). Post- group debriefing and the use of field notes further en-
hanced reflexivity.
Focus group questions were rooted in evidence on pan-
demic clinical research and standards for good clinical practice 
in research.4,9,10 We used images and hypothetical scenarios of a 
moderate- risk influenza pandemic to stimulate discussion of par-
ticipating in the following three research scenarios: a point of care 
test evaluation (primary care), evaluation of a routinely used antiviral 
medication with known safety profile (primary care) and evaluation 
of a newer antiviral medication with known safety profile (hospital 
intensive care unit) (Box 1). We also asked about the acceptability of 
conducting research that uses excess from routinely collected clin-
ical samples, and enrolment to adaptive clinical trials (Box 1). We 
selected a moderate- risk pandemic influenza because an airborne 
virus, such as a novel influenza, is a likely candidate for an epidemic 
or pandemic spread that might affect European countries. Scenarios 
were aligned with clinical studies being conducted in PREPARE that 
aim to recruit patients from primary care and critical illness settings 
and that aim to generate evidence to inform clinical management of 
outbreak- related illness. We chose to avoid an outbreak with very 
high mortality, such as Ebola, which might polarize decisions and 
limit transferability of findings to a European context. We also asked 
about reasonable adjustments to research enrolment processes, 
that is from the point when a patient is identified as eligible to be 
invited into a study, through the process of information exchange to 
support their decision about participation, and, if selected, the pro-
vision of consent. Follow- up interviews aimed to capture  post- group 
reflections.
2.4 | Analysis
Focus groups and interviews were audio- recorded, transcribed ver-
batim and translated into English. Local researchers checked each 
stage for accuracy. Data were analysed using the framework ap-
proach, which follows a systematic process moving from data man-
agement to description to interpretation.11 We charted the focus 
group (NG) and interview (HS) data by identifying text that related 
to our study objectives as evidence of a particular theme. In this 
way, a visual overview of the data was produced from which pat-
terns, including similarities and differences, could be identified. In 
practice, this involved charting data related to each specific objec-
tive on multiple Excel spreadsheets, which then formed the basis 
for team discussions regarding emergent, explanatory themes. 
Charting the data enabled recognition of contradictory or opposing 
views. The process of charting gave rise to the initial coding frame, 
which was then sent to local researchers (MG, SA, MPV), who dou-
ble coded one of their focus group transcripts, and gave feedback 
on the analytic frame. At this point, the analytic process moved 
further into an interpretative stage where links between themes 
and cases were explored to expand the explanatory frame. In this 
higher- level analysis, we aimed to identify the range and diversity 
of factors influencing decision making and retrospectively applied 
decision- making theory12 in our analyses. NVivo 10 software (QSR 
International, Melbourne, Australia) was used to facilitate analysis.
2.5 | Rigour and quality criteria
We used the COREQ checklist when designing and reporting this 
study13 and adhered to the following rigour criteria14: description 
of context, of informants and of the research process, methodologi-
cal adequacy and reflexivity of the multidisciplinary research team. 
Throughout the research process, we actively sought opportuni-
ties to consider how multiple perspectives influenced the research 
process.
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2.6 | Ethical considerations
Researchers obtained local ethical approvals in each country. 
Informants gave voluntary, written informed consent, and researchers 
guaranteed anonymity, confidentiality and data protection.
3  | RESULTS
Table 1 reports the characteristics of the 80 informants. Results were 
generally consistent across countries unless otherwise indicated in the 
text. In our follow- up interviews, no informants felt they had been 
misrepresented or had revised their opinions.
3.1 | Public understanding of pandemics
Informants described pandemics using both rational and emotive ex-
planations. Rational descriptions included the origin, characterization, 
transmission, spread and consequences of a pandemic.
P3: …somewhere in Thailand a zoonotic virus mutates and 
infects 100 million people. (Poland)
P6: … half of the working population is no longer working 
because of.. whatever the long-term effect is. (Belgium)
Emotive descriptions included the unpredictability of an outbreak, 
the rapidity of spread, high mortality and difficulty with containment. 
Consequently, they described fear, crisis and panic as defining features 
of a pandemic.
P5: Well, everyone was worried about Ebola, not be-
cause there was one case, but because it could have 
gone out of control and we didn’t know how to tackle 
it, or we didn’t have the systems to fight against it. 
(Spain)
P9: …people die, there is no escape. (Poland)
Personal (eg illness and vaccination experience) and social factors 
(eg history, media, political drivers) shaped participant understandings 
and perceptions of pandemics. In Belgium, Spain and the UK, but not 
Poland, the media was described as sensationalizing and stereotyping 
pandemic outbreaks, resulting in potential desensitization to the real 
threat of a future outbreak.
P1: …. there’s so much panic in a lot of the press anyway 
especially in [name of paper] and [name of paper] that you 
become a little bit desensitised to everything … so when 
a new pandemic comes around you think, ‘okay swine flu 
didn’t really do that much to me’ (Wales)
Belgium 
(n = 16) Spain (n = 16)
Poland 
(n = 19) UK (n = 29)a
Gender
Female 10 11 11 15
Male 6 5 8 14
Age
Median (Interquartile 
range)
60- 69 (40- 69) 50- 59 (30- 70) 60- 69 (50- 69) 30- 39 (30- 49)
18- 29 0 0 2 7
30- 39 1 5 2 8
40- 49 5 2 0 7
50- 59 1 3 4 3
60- 69 7 1 10 4
>70 2 5 1 0
Nationality
Local (Belgian, Spanish, 
Polish, British)
16 14 19 27
Other 0 2 0 2
Parent or carer
Yes 11 3 12 17
No 5 13 7 12
Intensive care unit experience
Yes 1 1 - 6
No 11 15 - 23
Unsure 4 - 19 - 
aWe included data from two pilot focus groups held in the UK.
TABLE  1 Characteristics of focus group 
informants
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P3: But afterwards it doesn’t turn out to be nearly as bad 
as expected, all of it. A huge fuss is made about it in the 
press and in the end, OK well a lot of people were a bit 
sick (Belgium)
Informants referred to historical pandemics such as the Black Death, 
Cholera in London, Spanish flu and, more recently, Ebola. Awareness of 
these outbreaks contributed to a perception that pandemics, by defini-
tion, are highly infectious, spread rapidly and result in high mortality. In 
contrast, the 2009 swine flu (“H1N1”) pandemic was associated with 
expectations of milder illness. Public health information distributed 
through official channels was seen as trustworthy and as able to con-
tribute to a more balanced understanding of what pandemics involve. 
However, informants described particular news stories or events as 
having introduced new perspectives. For example, the social activism of 
a Catalan physician during the swine flu epidemic, who heavily criticised 
the pharmaceutical industry, was cited as a reason to be cautious about 
the motives of those conducting research. Informants also noted criti-
cisms of public health agencies and in one group, in Wales, informants 
reflected on the political dimension to pandemics, where political par-
ties are under pressure to respond effectively to pandemic outbreaks.
3.2 | Attitudes towards pandemic research and 
willingness to participate
Informants regarded pandemic research as valuable and potentially 
life- saving. In identifying research priorities, informants highlighted 
the potential impact of research outcomes on their own lives. They 
wanted effective treatment, accurate diagnosis and targeted and pub-
lic health information for example, on risks of infection, health pro-
tection and symptom recognition. Consequently, they saw value in 
research to understand the causes, route of transmission, clinical man-
ifestation, disease course and to identify at- risk groups. Informants 
also saw value in disease surveillance programmes and for research 
plans to be in place in anticipation of a future outbreak.
P10: (once the outbreak has started) it would be then too 
late for research (Poland)
Informants were generally willing to take part in the research scenarios 
we presented. However, they saw existing enrolment procedures as a barrier 
to their participation, due to the time required and the cognitive burden on 
patients when they were unwell or on relatives when their loved ones were 
unwell (eg in acute illness settings). Some informants felt enrolment pro-
cesses created suspicion and questioned the validity of prospective informed 
consent when they or members of their family were unwell or distressed.
P2: I’m thinking if you’re feeling that rough, you’re not 
thinking straight anyway so wrong decisions could be 
made (UK)
In Belgium, Spain and the UK, informants described desensitization 
to authorization processes as a consequence of being inundated with 
signing “terms and conditions” in daily life. As a result, authorization has 
become habitual and automatic and has lost meaning.
P6:… you sign things every day, …: you agree to the terms 
and condition …. Agreed? Bang. Do you know what you’ve 
signed? You’ve agreed…
P5/P4: That’s quite right, you sign lots of things…
P6: And then for scientific research you’re going to say: I 
have to sign all this, I don’t think it’s so bad to have to sign 
it. (Belgium)
A minority of informants felt that current regulations protected clini-
cians and researchers rather than research informants. However, on the 
whole, informants appreciated the protections afforded by research reg-
ulation and generally saw these as reassuring, professional and indicative 
that research was trustworthy.
P8: I think these consents, they are meant to cover the 
doctor’s back, not yours (Spain).
Informants saw pandemics as an exceptional circumstance and felt 
that different rules or thresholds for pandemic research should apply. 
They proposed abbreviated information sheets and consent forms and 
suggested alternative ways of exchanging information (pictures and brief 
videos) and taking consent (verbal or video consent taken by clinician). 
The need for accountability and a verifiable “paper trail” was factors 
influencing unacceptability particularly of verbal consent. For low- risk 
interventions or where there was little difference between what would 
happen if they took part in research compared with routine treatment (eg 
taking an already licensed medication), informants suggested automatic 
enrolment with opt- in or opt- out provision.
P9: I think it should be that everybody is opted in and opt 
out and that would be the fastest (UK)
P9: On the other hand: if the doctor prescribes something 
for us, we generally take it without thinking about whether 
it’s really suitable for the particular situation, and we don’t 
sign anything (Belgium).
P9: No, you can’t burden someone with such a decision.
P3: There’s no need. You can write a declaration of intent, 
just as you can write a declaration of intent on donating 
your organs after death. (Poland)
In endorsing these models of research enrolment, informants re-
ferred to organ donation initiatives. Thus, in Belgium and the UK (Wales), 
opt- out policies for organ donation were referenced. In Poland, parallels 
with opt- in to organ donation registers were made. For ICU research, in-
formants recognized the need for a third- party to consent on their behalf 
should they lack decision- making capacity. Preference was expressed 
for a close family member who could represent their wishes and values 
to decide. However, if family members were unavailable (for example, 
ill with the pandemic), some informants, particularly those with prior 
ICU experience, considered it acceptable for a doctor to decide on their 
6  |     GOBAT eT Al.
behalf. High levels of trust in health- care professionals and the relatively 
low risks of harm with involvement in the study determined acceptability.
3.3 | Factors influencing decisions about research 
participation
Decisions about participation were influenced by a complex interplay 
between personal attributes, research factors and contextual cues. 
Personal factors, such as age, life stage and previous ICU experience, 
were influential. For example, older informants felt their age made 
them more “philosophical” and described feeling more socially con-
scious, while parents of younger children described needing to be es-
pecially cautious about exposing themselves to risk. Research factors, 
particularly the benefits and risks or burdens of participation, were 
deliberated. These were judged contextually. For example, when de-
liberating about participation in the ICU scenario, risks associated with 
acute illness and the pandemic were considered.
Perception of immediate personal benefit was a strong motivator 
to take part. For example, a more accurate diagnosis was offered as 
justification to be part of an evaluation of a point of care test (POCT) 
in primary care (scenario 1).
P4: If they do this test, regardless how reticent you are… if 
you can know there and then whether you are infected…
P7: Of course, then yes…
P4: … or whether you aren’t infected… I think you should 
assume it is worth it… (Spain)
Perceptions regarding the benefit of antiviral medication in primary 
care (scenario 2) were mixed, but some respondents saw benefits to re-
ceiving this trial intervention if offered.
P6: f it shortens the period of infection for 1 week… then 
I would. (Spain)
In the ICU scenario (scenario 3), informants perceived that they 
would receive more effective treatment if in a trial than if not. Some in-
formants said they would only participate if guaranteed to receive an 
experimental trial intervention. Fear, driven by a perception that that no 
known effective treatment may be available for a life- threatening illness 
meant that informants placed greater hope in the intervention’s superior-
ity. Informants were also motivated by altruism, social responsibility and 
by contributing to medical knowledge in the “long- term.” They wanted 
to receive feedback about the outcome of research they supported and 
felt feedback of results was a neglected aspect of research participation, 
which reduced the chances of subsequent research involvement.
Benefits were weighed against perceived risks and burdens of 
research participation. For example, informants saw a hypothetical 
POCT requiring a nasal swab sample in primary health care (scenario 
1) as minimally invasive and low risk and used phrases such as “its 
just a swab,” “sounds harmless” and “no bother” as justifications for their 
decision to take part should they be invited. Risks of side- effects and 
scepticism that medication was necessary were reasons given not to 
take part in the primary care medication study (scenario 2).
P1: … I thought that with a viral infection you just have 
to let it run its course. …. So I’d have more objections in 
this case. I think: leave me alone; I’ll let it run its course…. 
(Belgium)
In the ICU scenario (scenario 3), risks and burdens were judged pro-
portionate to the context of critical illness in which the decision about re-
search participation was being made. Informants expressed less concern 
about potential side- effects of new interventions, describing the critical 
illness scenario as being “serious” and “you’re in dire straits” (Poland).
However, informants also described making a more instinctive, in-
tuitive decision based on personal pre- disposition, rapid appraisal and 
perceptions of trust, particularly when feeling fearful or unwell.
P1: I think that if you’re not sick, you definitely think like: 
would I do it or wouldn’t I? Weigh up the pros and cons 
more. And think about it. And if you’re ill, you’d think more 
radically like: no, leave me alone. Or: yes, do it. (Belgium)
P7: I would usually take part, because this is my way of 
being (Spain)
In primary care, informants described a high level of trust in clinicians 
that had developed over time and with continuity of care. Several infor-
mants spoke of actively seeking to consult with primary care clinicians 
they trust; care pathways in Poland and Belgium allow patients to choose 
their primary care physician and this is possible to some extent in Spain 
and the UK. Informants with experience of ICU spoke of trust developing 
very rapidly with treating clinicians by virtue of the intensity of acute 
illness and vulnerability coupled with perceived expertize of the clinical 
team, including the quality of their communication. Informants felt they 
would seek advice from these clinicians about research participation. A 
clear, minority view was also expressed suggesting that informants may 
feel unable to refuse participation in the context of an existing relation-
ship with their treating clinician.
3.4 | Acceptability of using routinely collected 
clinical samples for research
Informants supported the use of routinely collected clinical samples 
being available for pandemic research. Altruism was a key motivation 
and informants considered it prudent and efficient not to waste clini-
cal samples. Informants mostly thought that this should be allowed 
without specific consent, as long as safeguards were in place to pro-
tect against identification of the individuals.
P3: I wouldn’t mind.
P8: Yes, I agree, I think it is important to make the most 
of it because… if it is anonymous, if it is only to do more 
research, then they shouldn’t have to ask for permission 
again. At the signing stage, you could indicate ‘I sign up to 
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this research and for the following research studies derived 
from it’. (Spain)
However, a minority of respondents from all countries wanted up-
front information about how and for what their sample might be used. 
They also sought assurance that their samples would not be used for 
commercial purposes and were generally less trusting of research funded 
by industry sponsors, or where financial gain was the main ultimate mo-
tive. A counter- argument was also raised, highlighting the need to sup-
port investment required to develop new, more effective products.
3.5 | Views on Participating in Adaptive 
Clinical Trials
Informants grasped the concept of the response- adaptive clinical trial 
design and viewed this as well suited to a pandemic context and liked 
the novelty, flexibility and potential for enhanced personal benefit.
P1: The second one makes more sense …because you can 
adjust the adaptive trial. (Belgium)
P7: The other one takes more into account the person. 
(Spain)
They took a pragmatic view about the potential disadvantage to 
being enrolled in a response- adaptive trial at an earlier stage, when less 
was known about which treatment was performing better.
P2: you’re ill when you’re ill aren’t you?
P8: exactly (Wales)
A minority view held that the adaptability of the design implied that 
researchers were uncertain, “fiddling in the middle” (P4, UK 04) and that 
“perhaps traditional is safer, it can’t go wrong” (P8, Spain10). On balance, 
informants felt that being given information about study design was less 
important than information about risk, burdens and benefits in informing 
their decision about taking part or not. If study design information was to 
be available upfront, informants said they would want to know about the 
potential for adaptation and how that might impact their involvement.
P5: We consent to participate in the study, don’t we? And 
the study techniques, well, this is a matter for the doctor 
who conducts it. (Poland)
4  | DISCUSSION
We present a wide range and diversity of public views in four 
European countries about perceptions of research participation dur-
ing a pandemic outbreak of a novel Influenza- like- illness. Informants 
supported the need for clinical research during a pandemic outbreak 
and endorsed simplified, proportionate research enrolment processes. 
Informants valued regulatory oversight of clinical research but also 
described having become desensitized to consent and “disclaimer” 
rituals and would not want to be overburdened with decision making 
about participation in low- risk research when they were unwell. They 
viewed opt- out consent models for low- risk research as acceptable 
and, at times, preferable.
Continued public engagement about clinical research partici-
pation is essential, in particular, to clarify the distinction between 
clinical care and research participation and to mitigate therapeutic 
misconception.15 In a pandemic outbreak, therapeutic misconcep-
tion may be amplified as agreeing to be part of a trial might be seen 
as providing unique access to novel or better treatments, rather than 
access to treatments with, as yet, unknown effectiveness or supe-
riority.15 While therapeutic misconception may inadvertently facil-
itate recruitment into clinical trials in the short term, in the longer 
term, it undermines trust in science, transparency and good clini-
cal practice. In a pandemic outbreak, it is likely that public health 
agencies would determine whether promising interventions should 
be routinely available to the public. Novel therapeutic agents may 
only be available for testing in a randomized controlled trial if suf-
ficient uncertainty regarding their efficacy remained. Nevertheless, 
public perception that novel research interventions are superior and 
therapeutic misconception should be addressed explicitly during 
recruitment itself. Response- adaptive trials may be appropriate for 
assessing certain types of interventions in pandemic research1,16 
and may go some way to meet therapeutic expectations about trial 
participation in that these trial designs allow pre- specified changes 
to the chances of a participant being allocated to an intervention 
arm that starts to perform better,17 thus participants joining a study 
later may be more likely to receive an effective intervention.18,19 
Some have raised concern that such studies can be complex to ex-
plain to patients,20,21 and so could further complicate enrolment in a 
public health emergency. Our informants could grasp the response- 
adaptive trial design and saw it as advantageous, particularly during 
a pandemic outbreak, but did not necessarily consider information 
about study design as a priority during an outbreak. Our findings 
confirm the general public’s acceptance of donating excess mate-
rial from routinely collected clinical samples for biomedical research 
provided safeguards are in place to protect against identification of 
the individuals and that the research was being performed primarily 
for patent benefit rather than to make a profit.22
Decisions about participation in research were influenced by a 
complex interplay between personal attributes, research factors and 
contextual cues. In some scenarios, informants deliberated, weighed 
the risks and benefits of taking part in the context of perceived ill-
ness severity and pandemic threat. Informants also described a more 
instinctive decision- making style. They described a pre- disposition to 
take part in clinical research or not, and then sought cues, particu-
larly regarding trustworthiness, to confirm or contradict that position. 
Others have made similar observations suggesting that rapid decision 
making at a time of increased risk and uncertainty may reflect a natural 
way that people have evolved to competently navigate complex envi-
ronments.23 These insights about the nuances of participant decision 
making challenge assumptions underpinning our current models of 
8  |     GOBAT eT Al.
research enrolment and suggest they may be oversimplified. They also 
highlight the importance of public trust as an important foundation for 
involvement during a pandemic outbreak. Focus group informants in 
all countries made reference to national events that had either eroded 
or enhanced trust in both commercially and publically funded institu-
tions. For example, Poland was the only country not to stockpile the 
vaccine available during the swine flu pandemic, which our informants 
saw as prudent. In the UK, informants trusted the nationally funded 
health service and described an obligation to “give back” wherever 
possible, thereby justifying research participation.
Through their participation in this study, informants gained insight 
and knowledge, formulated their position on research participation 
and spoke with family about research wishes. While informants did 
not necessarily change their views about research participation, they 
described increased awareness and valued the opportunity for debate. 
Other studies have identified similar effects.24 People need opportu-
nity to formulate their views on research participation and commu-
nicate these with people close to them. National initiatives such as 
organ donation have stimulated and normalized discussions of peo-
ple’s wishes. Similar campaigns might contribute to a broader public 
discourse about research participation. Informants in Belgium, Poland 
and the UK (Wales) all made reference to organ donation. Interestingly, 
discussion about organ donation was not raised spontaneously in the 
Spanish groups despite Spain leading the way in opt- out organ dona-
tion. We have developed a public facing report of our findings to invite 
continued engagement among our study participants and to extend 
discussion and debate among a wider audience (Box 1).
4.1 | Strengths and weaknesses
Sample sufficiency was attained with the use of complementary 
techniques and the richness of data collected across four coun-
tries. Richness of data was achieved, in part, by skilful group fa-
cilitation through which informants felt comfortable to change their 
opinions or express discrepant views; researchers actively elicited 
individual and group deliberation. Similarity of findings in the differ-
ent countries and with findings from other studies, using follow- up 
interviews with participants holding discrepant views and reflexive 
discussions on analysis among researchers, supports the credibility 
of our research. Our sample is not reflective of the age group most 
affected during the H1N1 pandemic; however, we have no way of 
predicting in advance which age groups will be affected in future 
pandemics. Our groups were largely mono- cultural, and the views 
of minority ethnic groups are not represented. As respondents vol-
unteered to participate, we assume some responder bias. We used 
hypothetical scenarios and views may have been different had we 
used different scenarios, or following actual research participation 
during a pandemic. Process evaluations conducted as part of pan-
demic clinical research are required to offer insight into participants’ 
actual experience. Despite training, there was some variation in the 
way informants were recruited and data were collected in different 
countries, which may have impacted our ability to compare across 
countries. The median age differences in different country data also 
limits our ability to compare directly across countries. Appropriate 
to the hypothesis generating nature of this work, we worked with 
a purposive sample which is designed to provide transferrable but 
not generalizable data.25 We have used these findings to develop a 
cross- sectional survey of public opinion that will allow us to quan-
tify views and consider generalizability in nationally representative 
samples in eight countries within the Organisation for Economic 
Co- operation and Development (OECD).
5  | CONCLUSIONS
This work underpins the call to minimize regulatory burden for pan-
demic clinical research proportionate to the potential risk of harm. 
Pandemic research requires flexibility, adaptability and co- ordination 
and sets an imperative for change in the current paradigm of research. 
The public value safeguards of research regulation, but these should 
not present disproportionate, “one- size- fits- all” barriers to their par-
ticipation. Opportunities for change may lie in new regulations guiding 
European clinical trials that now make provision for a new category 
of clinical study that poses minimal risk to participants.26 Newly pub-
lished ethical guidelines also offer advice regarding modifications to 
informed consent.27 Effective pandemic preparation for clinical re-
search requires active public involvement to mitigate therapeutic mis-
conception, engender trust and promote innovation to the research 
process.
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